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Available online 30 December 2015Inﬂammatory cells such as microglia need energy to exert their functions and to maintain their cellular integrity
andmembrane potential. Subsequent to cerebral ischemia, inﬂammatory cells inﬁltrate tissuewith limited blood
ﬂow where neurons and astrocytes died due to insufﬁcient supply with oxygen and glucose. Using dual tracer
positron emission tomography (PET), we found that concomitant with the presence of inﬂammatory cells, trans-
port and consumption of glucose increased up to normal levels but returned to pathological levels as soon as in-
ﬂammatory cells disappeared. Thus, inﬂammatory cells established sufﬁcient glucose supply to satisfy their
energy demands even in regions with insufﬁcient supply for neurons and astrocytes to survive. Our data suggest
that neurons and astrocytes died from oxygen deﬁciency and inﬂammatory cells metabolized glucose non-
oxidatively in regions with residual availability. As a consequence, glucose metabolism of inﬂammatory cells
can mask metabolic deﬁcits in neurodegenerative diseases. We further found that the PET tracer did not bind
to inﬂammatory cells in severely hypoperfused regions and thus only a part of the inﬂammation was detected.
We conclude that glucose consumption of inﬂammatory cells should be taken into account when analyzing
disease-related alterations of local cerebral metabolism.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Cerebral ischemiaIntroduction
Harmful or beneﬁcial — disorders of the brain may induce neuroin-
ﬂammation affecting the course of disease (Graeber and Streit, 2010;
Graeber, 2010). After an ischemic injury, the peak of the inﬂammatory
response is typically observed one week after the onset of ischemia
(Hallenbeck et al., 1986). In ischemic regions, neurons and astrocytes
die because of insufﬁcient supply of nutrients and oxygen. Inﬂammatory
cells, however, also rely on energy supply to exert cellular functions and
to maintain their membrane potential. In a double tracer long-term
follow-up positron emission tomography (PET) study in rats we analyzed
the development of inﬂammation in relation to local glucose metabolism
following permanent occlusion of the middle cerebral artery (MCAo).
Inﬂammation was localized and quantiﬁed using [11C]PK11195, a PET
tracer that binds to the translocator protein expressed by activated mi-
croglia and macrophages (Banati, 2002; Politis et al., 2012; Rojas et al.,tabolism Research, Gleueler Str.
. This is an open access article under2007; Thiel and Heiss, 2011). Since [11C]PK11195 does not allow for dif-
ferentiation, we summarize here activated microglia and microglia- or
monocyte-derived macrophages as inﬂammatory cells, keeping in mind
that other types of inﬂammatory cells could be involved. Glucose metab-
olism was measured using [18F]-2-ﬂuoro-2-deoxy-D-glucose ([18F]FDG)
as PET tracer. Additionally, we measured blood ﬂow 1 h after MCAo
using [15O]H2O-PET for localization of the primarily affected ischemic ter-
ritory and performed structural magnetic resonance imaging (MRI) be-
fore each PET scan. In vivo data were compared with ex vivo
immunostaining.
Materials and methods
Animals and Surgery
All animal procedures were performed in accordance with the Ger-
man Laws for Animal Protection and were approved by the local animal
care committee and local governmental authorities (LANUVNRW).Male
Wistar rats (n=5, Janvier, France;weight: 320 to 363 g; age ~ 10weeks;
pairwise housed in type-4 cages ﬁlled with Lignocel in an inverse 12 h
day–night cycle with lights on at 8:30 pm in a temperaturethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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formed between 9 am and 4 pm) were anesthetized with 5% isoﬂurane
and maintained with 2.5% isoﬂurane in 65%/35% nitrous oxide/oxygen.
Throughout the surgical procedure and the MRI and PET imaging proce-
dures, body temperature was maintained at 37.0 ± 0.5 °C using a ther-
mostatically controlled heating pad (MEDRES, Cologne, Germany).
Before acute PET imaging, animals were prepared for induction of ische-
mia using macrospheres (Gerriets et al., 2004). Brieﬂy, the left common
carotid artery, internal carotid artery, and external carotid arterywere ex-
posed through a midline incision of the neck and the external carotid ar-
tery and the pterygopalatine branch of the internal carotid artery were
ligated. A PE-50 catheter was ﬁlled with saline and two TiO2
macrospheres (diameter of 0.315–0.355 mm; BRACE, Alzenau,
Germany). This catheter was inserted into the common carotid artery,
advanced to the origin of the pterygopalatine artery, and ﬁxed in place.
After placing the rats in the micro-PET scanner and running baseline re-
gional cerebral blood ﬂow (rCBF) measurements using [15O]H2O as trac-
er, macrospheres were injected through a saline-ﬁlled catheter placed in
the internal carotid artery to occlude the middle cerebral artery. Follow-
ing PET imaging, the catheter was removed and the animals were
allowed to recover. Each animal was additionally imaged by T2-
weighted MRI and PET using [11C]PK11195 and [18F]FDG at baseline
(7 days before MCAo) as well as at days 2, 7, 14, 21 and 42 after MCAo.
During the experiment, all animals received an intensiﬁed care with
moistening of food pellets, subcutaneous saline injections (5 mL
0.9%NaCl/day for 8 days) and an intra- and postoperative analgesia with
Carprofen (Rimadyl®; 5 mg/kg/day s.c. for 3 days).
PET
PET imaging was performed using a microPET Focus 220 scanner
(Concorde Microsystems, Inc, Knoxville, TN; 63 image planes; 1.5-mm
full width at half maximum). For each animal and each imaging session
transmission data from a Co57 point source were acquired for attenua-
tion correction. During induction of ischemia rats received an intrave-
nous bolus injection of [15O]H2O (59–89 MBq/rat in 0.5 mL) before as
well as 5, 30, and 60 min after MCAo without changing the position of
the animals in the PET scanner. Emission data were acquired for
2 min. Thereafter, an intravenous bolus of [18F]-2-ﬂuoro-2-deoxy-D-
glucose ([18F]FDG) (52–74 MBq/rat in 0.5 mL) was injected into the
tail vein at 75 min after embolization of macrospheres, and emission
data were acquired for 60 min.
At baseline (7 days before MCAo) as well as 2, 7, 14, 21, and 42 days,
rats received an intravenous bolus injection of [11C]PK11195 (59–89
MBq/rat, speciﬁc activity 18.5–81.4 GBq/μmol) in the tail vein. EmissionFig. 1. Cerebral blood ﬂow 1 h after permanent occlusion of the middle cerebral artery. The r
[15O]H2O PET. Data is from the same rat and spatially co-registered to the data shown in Fig. 2
markers. The red line indicates the boundary of the brain.data were acquired for 30 min and the animals remained in the μPET-
scanner without changing their position. 100 min after injection of
[11C]PK11195 (~5 half-lives of the [11C]-labeled tracer) a bolus of
[18F]FDG (52–74 MBq/rat in 0.5 mL) was injected in the tail vein and
emission data were acquired for 60 min.
[18F]FDG and [11C]PK11195 datawere histogrammed in time frames
of 6 × 30 s, 3 × 60 s, 3 × 120 s, and either 12 × 240 s for [18F]FDG
or 4 × 240 s for [11C]PK11195, Fourier rebinned, and images (voxel
size: 0.4 mm × 0.4 mm × 0.8 mm) were reconstructed using 2-
dimensional ﬁltered back projection. Binding potential of the radiotrac-
er [11C]PK11195 was calculated using the simpliﬁed reference tissue
model (SRTM) using the contralateral hemisphere as reference region
(Lammertsma and Hume, 1996). [15O]H2O data were Fourier rebinned
and images were reconstructed using 2-dimensional ﬁltered back pro-
jection. CBF was assessed as percentage injected dose of [15O]H2O aver-
aged over 2 minute acquisition time. A 1.5 mm Gaussian Filter was
applied to the CBF images.
An image derived input function was extracted from the [18F]FDG-
PET data and parametric images of the kinetic constants were deter-
mined by a voxel-by-voxel application of a two-tissue-compartment ki-
netic model (Backes et al., 2011). K1 is the rate constant for [18F]FDG
transport from blood into the brain tissue and is related to regional cere-
bral blood ﬂow (Walberer et al., 2012). The metabolic rate constant or
net inﬂux rate constant for [18F]FDG is given by Ki = K1 k3 / (k2 + k3).
The cerebral metabolic rate of glucose CMRglc is given by: CMRglc =
Kglc Cp, where Kglc is the net inﬂux rate constant of glucose (Kglc = Ki /
[0.38 + 1.22 Ki/K1]) and Cp the plasma glucose level. Note, that Kglc
takes into account changes of the lumped constant that result from
changes in the relative contributions of glucose transport andhexokinase
activity (Backes et al., 2011). The plasma glucose level was determined
after each [18F]FDG PET measurement from a tail vein blood sample
(measured values: 75–233 mg/dL, mean = 128.5 ± 28.8 mg/dL).
Magnetic resonance imaging
At baseline (7 days before MCAo) as well as 2, 7, 14, 21 and 42 days
after induction of ischemia, rats were (re-)anesthetized with isoﬂurane,
and experiments were conducted on a 4.7 T BioSpec system (Bruker
BioSpin, Ettlingen, Germany) with a 30 cm bore horizontal magnet,
equipped with a self-shielded gradient system (max gradient:
100 mT/m; rise time: b250 μs). Radio frequency transmission was
achieved with a Helmholtz coil (12 cm diameter), and the signal was
detected with a 22 mm diameter surface coil. The animals were posi-
tioned prone in a dedicated cradle using a stereotactic head holder
with the surface coil placed directly over the head. A multisliceegion supplied by the MCA was characterized by a severe reduction of CBF measured by
. Left: coronal section, right: axial section. Locations of the sections are indicated by white
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Fig. 3. Inﬂammation and glucose metabolism in the region of primary inﬂammation ([11C]PK11195-BPND N 1 at day seven after MCAo) (n = 5). (A) Glucose consumption rate constant
(Kglc, red) and the rate constant for unidirectional transport of glucose from blood to brain tissue (K1, blue) over inﬂammation level (BPND) before and at different time points after
MCAo. (B) Data from individual rats for time points after MCAo. The lines are linear ﬁts. BPND was signiﬁcantly correlated with Kglc (r = 0.65, p = 0.0005) and close to signiﬁcantly
correlated with K1 (r = 0.39, p = 0.0508) (C) Time course of glucose consumption rate constant (red) and inﬂammation level (BPND, black). (D) Time course of CMRglc in the region of
primary inﬂammation (VOI) and the healthy contralateral hemisphere and their ratio (E). (F) CMRglc,VOI/CMRglc,c data from individual rats (grey), averages for each time point, and
linear ﬁt for time points after MCAo (r = 0.81, p b 0.0001). Asterisks indicate signiﬁcant differences from baseline (*p b 0.05, **p b 0.01, ***p b 0.001).
Fig. 2. Inﬂammation and glucosemetabolism after occlusion of themiddle cerebral artery (MCAo). Left column: glucose consumption rate constant (Kglc) determined from [18F]FDG-PET;
middle column: bindingpotential (BPND) of [11C]PK11195binding for localization of inﬂammation; right column: structural T2weightedMRI image. Top row: twodays afterMCAo,middle
row: 7 days after MCAo, bottom row: 42 days after MCAo. In the region marked by the crosshairs, the presence of inﬂammation at day seven was accompanied by a relative increase of
glucose metabolism from day 2 to day 7. Data are taken from the same rat and spatially co-registered to the data shown in Fig. 1. In each column left: coronal section, right: axial section.
Locations of the sections are indicated by white markers.
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Table 1
Region of primary inﬂammation (PK11195-BPND N 1) at day 7 after MCAo. Volume of the region, mean BPND, CMRglc as fraction of the contralateral hemisphere, and CBF reduction in the
region at 1 h after MCAo as fraction of injected dose of [15O]H2O in VOI relative to the contralateral hemisphere are listed for each individual animal.
Rat # VOI vol. (μL) PK11195-BPND(d7) CMRglc,VOI/CMRglc,ctra(d7) [15O]H2OVOI/[15O]H2Octra(1h)
1 248.4 1.41 0.88 0.72
2 154.5 1.26 0.89 0.71
3 60.6 1.23 1.06 0.56
4 175.6 1.44 1.02 0.45
5 86.6 1.54 0.91 0.62
Mean ± SE 145.2 ± 33.6 1.38 ± 0.06 0.95 ± 0.04 0.61 ± 0.05
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multi-echo trains in twenty contiguous T2-weighted coronal slices with
a thickness of 1 mm (relaxation time/echo time = 4279/12.5 msecs, 16
echoes, ﬁeld of view= 4.6 cm, matrix 128 × 128) for the detection of in-
farct and edema. During scanning, body temperature and respiration rate
were monitored and maintained using a combination of in-house equip-
ment and DASYLab 9.0 (DasyLab, Moenchengladbach, Germany).
Radiochemistry
The radiolabeled tracers [15O]H2O, [11C]PK11195 and [18F]FDGwere
produced as described previously in more detail (Schroeter et al., 2009;
Walberer et al., 2012).Fig. 4. (A) [11C]PK1195binding sevendays after occlusion of the leftMCA. Post-mortemNeuN (B
later. At day 42, the predominant part of the region with high [11C]PK1195 binding is necrotic.Histology and Immunohistochemistry
After PET-measurements at day 42, animals were decapitated under
deep anesthesia with isoﬂurane. The brains were rapidly removed, fro-
zen in 2-methylbutane, and stored at -80°C prior to further histological
and immunohistochemical processing. Adjacent serial coronal brain
sections were cut at 500 μm intervals (slice thickness 10 μm) and
stainedwith hematoxylin and eosin (H&E) according to standard proto-
cols. The mAb against the complement receptor 3/CD11b identiﬁed
microglia/macrophages (clone OX42, dilution 1:1000, AbD Serotec, Ox-
ford, UK, cat-#MCA275R).Microglia activationwas assessed by staining
forMHC class II (cloneOx6, dilution 1:400, AbD Serotec, Oxford, UK, cat-
#MCA46G). Phagocytic cells were identiﬁed with mAb ED1 (clone ED1,), ED1 (C), andOx-42 (D) stainingof the samebrain region and the same animalﬁveweeks
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marker NeuN (clone A60, dilution 1:1000, Millipore, Billerica, USA, cat-
# MAB377) was used to assess neuronal integrity in the peri-infarct
zone, in order to exactly distinguish infarcted from intact tissue. For vi-
sualization, we used the ABC Elite kit (Vector Laboratories, Burlingame,
CA, USA) with diaminobenzidine (Sigma, Munich, Germany) or Vector
SG substrate kit for peroxidase (Vector laboratories, Burlingame, CA,
USA.) for anti-NeuN staining as the ﬁnal reaction product.
Image analysis
For co-registration of PET-, MRI- and histological images, the image
analysis software VINCI was used (Cízek et al., 2004). PET and MR im-
ages were ﬁrst manually co-registered to a 3D brain atlas constructed
from brain slices presented by Swanson (Swanson, 2003). Slices that
corresponded to the histological slices were then identiﬁed in the 3D
brain atlas and saved as 2D images together with the co-registered
PET and MR images. Compositions of the 2D PET, MRI and histological
images were performed using GIMP an open source software for
image processing (http://gimp.org).
For analysis of the time course of inﬂammation in relation tometab-
olism, in each individual animal all voxels in the 3D PET datasets with a
binding potential of [11C]PK11195 BPNDN1 seven days after MCAFig. 5. [11C]PK11195 binding and immunostaining at day seven afterMCAo in two representative
ED1 and Ox-42 staining. The images below show a detailed analysis of the cellular compositio
comparison to the homologous region in the healthy contralateral hemisphere (‘Control’).
performed for neurons (NeuN), astrocytes (GFAP), oligodendrocytes (Olig2), microglia/mac
nuclei are stained in blue by Hoechst 33342 (Hoe). Additional staining for lactate-dehydrog
lactate characteristic for non-oxidative glucose metabolism.occlusion were marked. For each animal the average binding potential,
K1, and Kglc in this region were determined for baseline, days 2, 7, 14,
21, and 42.
Statistics
One way repeated measures ANOVA was performed for K1, Kglc and
BPND for the factor “time”. Differences to baseline were tested using
pairwise multiple comparison with Holm–Sidak p-value adjustment.
Correlation of K1 and Kglc with BPND afterMCAowas tested using a Pear-
son product-moment correlation test. Calculations were performed
using the software package R (http://www.R-project.org/). All values
are given as mean ± standard error.
PK11195 binding and histology at day seven after MCAo
In order to support our ﬁndings from this study with histologic data
acquired at day 7 after MCAo we re-analyzed histologic data in relation
to PK11195 uptake from a study performed by our group that had al-
ready been published (Schroeter et al., 2009). In brief, [11C]PK11195-
PET and subsequent histological staining with H&E, Ox42, and ED1
was performed in 5 male Wistar rats seven days after MCAo following
the experimental procedures described above. The MCA was occludedanimals. The top rowgives anoverviewof the location of [11C]PK11195 binding relative to
n in a representative [11C]PK11195-postive region (column labeled by ‘[11C]PK11195’) in
The approximate location is indicated on the ED1 slices by a black arrow. Staining was
rophages (Iba1, Ox42), and phagocytizing macrophages (ED1). In the fused images cell
enase-5 (LDH-5) indicates regions with predominant transformation of pyruvate into
59H. Backes et al. / NeuroImage 128 (2016) 54–62using themacrospheremodel in the sameway as in this study. Here we
re-analyzed the data and performed additional stainings of brain sec-
tions from two rats in order to determine the status of brain tissue in
the region of maximum [11C]PK11195 binding at day seven. To verify
the absence of neurons, astrocytes and oligodendrocytes within the
[11C]PK11195-positive region we used the neuronal marker NeuN
(clone A60, dilution 1:500 for ﬂuorescence, Millipore, Billerica, USA,
cat-#MAB377) to assess neuronal integrity, an antibody against glial ﬁ-
brillary acidic protein (GFAP, clone GA5, dilution 1:500, Millipore,
#AB5320, Darmstadt, Germany) as marker for astrocytes, and anFig. 6. [11C]PK11195 binding and cerebral blood ﬂow (CBF). (A) Coronal, axial, and sagittal sec
healthy hemisphere. (B) [11C]PK11195 binding at day 7 after MCAo in the same animal. (C)
(mean ± SE) and CBF in n = 5 rats. There is a systematic decrease in [11C]PK11195 binding inantibody against oligodendrocyte transcription factor 2 (Olig2, dilution
1:300, AB9610, Millipore, Darmstadt, Germany) for oligodendrocytes.
The monoclonal antibody (mAb) against the complement receptor 3/
CD11b identiﬁed microglia/macrophages (clone OX42, dilution 1:300
for ﬂuorescence, AbD Serotec, Oxford, UK, cat-# MCA275R). Microglia
activation was assessed by staining for Ionized calcium binding adapter
molecule 1 (Iba1, dilution 1:500,Wako Pure Chemical Industries, Osaka,
Japan, cat.#019-19741). Phagocytic cells were identiﬁed with mAb ED1
(clone ED1, 1:500 for ﬂuorescence, AbD Serotec, Oxford, UK, cat-#
MCA341). To detect areas with predominantly glycolytic metabolismtion of CBF measured by [15O]H2O-PET 60 min after MCAo shown as fraction of CBF in the
Overlay of [11C]PK11195 binding and CBF. (D) Regional analysis of [11C]PK11195-BPND
regions with low CBF.
60 H. Backes et al. / NeuroImage 128 (2016) 54–62we stained for Lactate Dehydrogenase Isoenzyme 5 (LDH-5), an enzyme
that is transcriptionally regulated by the hypoxia inducible factors (HIF)
1a and 2a (dilution 1:250, #ab101562, Abcam, Cambridge, UK). Second-
ary antibodies for ﬂuorescence microscopy were goat-anti-rabbit 568
and goat-anti-mouse 488 (Alexa Fluor, Invitrogen/Life Technologies,
Carlsbad, CA, USA). For nuclear co-staining, Hoechst 33342 (Life Technol-
ogies, Darmstadt, Germany) was applied after the secondary antibody.
Representative images of the [11C]PK11195-positive and the homol-
ogous region in the healthy hemisphere were taken using an inverted
ﬂuorescence phase-contrast microscope (Keyence BZ-9000E, Osaka,
Japan) with 4×, 20×, and 40× objectives.
Results
Acute changes of CBF and metabolism after permanent occlusion of the
MCA
We analyzed development of CBF during the ﬁrst hour after MCAo
with the help of serial [15O]H2O PET imaging (Fig. 1). The results wereFig. 7. Inﬂammation and hypometabolism inpatientswith Parkinson's disease anddementia. Th
right column shows regions with signiﬁcant reduction of CMRglc as identiﬁed by using [18F]FDG
with severe hypometabolism and no [11C]PK11195 binding, green arrows indicate those regio
ﬁgure is composed from images taken from Figs. 1 and 3 in Edison et al. (2013). Reprinted b
(2013)), copyright 2013.]already published and extensively discussed in (Walberer et al., 2012).
In short, we found that CBF in theMCA territory decreased substantially
within 30min after occlusionwith no relevant changes between 30 and
60 min. We conclude that after permanent occlusion regional ﬂow at
60 min is representative for future damage. CBF at 60 min correlated
well with the unidirectional transport parameter of FDG K1. A combina-
tion of the kinetic parameters of FDG K1 and Ki allowed for the discrim-
ination of infarct core (low K1, low Ki) from early viable tissue (low K1,
high Ki).
Development of inﬂammation and metabolism during six weeks after
MCAo
The maximum of [11C]PK11195-BPND as measure for inﬂammation
was observed seven days after stroke in the border zone of the ischemic
core (Figs. 2 and 3) and in the thalamus of the affected hemisphere. In-
ﬂammation in the thalamus persisted until the end of the six weeks ob-
servation period. Note, the thalamus is not part of the supply territory of
the MCA, but since its neurons project to severely injured corticale left columnshows inﬂammation as revealed by a signiﬁcant binding of [11C]PK11195. The
-PET (note that brighter color indicates reducedmetabolism). Blue arrows indicate regions
ns with a high [11C]PK11195 binding which do not show reductions in metabolism. [This
y permission from Macmillan Publishers Ltd: Neuropsychopharmacology (Edison et al.
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2009, Schroeter et al., 2006). In the following we focus on primary in-
ﬂammation in directly affected brain regions.
In each animal, we identiﬁed primary inﬂammation by a binding po-
tential (BPND) of [11C]PK11195-BPND N 1 seven days after stroke (exclud-
ing the thalamus). The threshold of BPND N 1 is well above the BPND noise
level on a voxel basis,which is in the order of 0.3. BPND is ameasure for the
number of activated microglia and macrophages per volume and as such
a surrogate measure of inﬂammation. The anatomic location of primary
inﬂammation was restricted to the affected hemisphere in each animal
but differed individually due to inter-individual variability of the ischemic
territory. We therefore analyzed the time course of glucose transport and
metabolism as well as the level of inﬂammation in the respective region
of each animal (Table 1, Figs. 2 and 3). At 1 h after MCA occlusion CBF
was reduced by 39% (28%–55%) in this region (Table 1). MCAo had an
overall effect on K1 (F(5,20) = 4.86, p = 0.005), Kglc (F(5,20) = 7.01,
p b 0.001), and BPND (F(5,20)= 28.82, p b 0.001). BeforeMCAo, metabo-
lism was normal (K1 = 0.11 ± 0.004 mL/mL/min, Kglc = 0.036 ±
0.003 mL/mL/min) and, as expected, no inﬂammation was detected
(BPND =−0.06 ± 0.13). Two days after stroke, glucose transport and
consumption were reduced in the region of primary inﬂammation
(K1 = 0.099 ± 0.008 mL/mL/min, p = 0.095; Kglc = 0.025 ± 0.002 mL/
mL/min, p = 0.026), indicating severely reduced glucose metabolism.
No signiﬁcant level of inﬂammation could yet be observed (BPND =
0.08 ± 0.06, p = 0.38). Seven days after the onset of ischemia, the level
of inﬂammation reached its maximum (BPND = 1.38 ± 0.06, p b 0.001)
and remained high for more than one week (day 14: BPND = 0.74 ±
0.16, p b 0.001; day 21: BPND = 0.50 ± 0.11, p = 0.003). Glucose trans-
port andmetabolism returned to normal (i.e., baseline) levels in this par-
ticular region during that time (day 7: K1 = 0.11 ± 0.002 mL/mL/min,
p = 1.0; Kglc = 0.039 ± 0.003 mL/mL/min, p = 0.77; day 14: K1 =
0.12 ± 0.006 mL/mL/min, p = 1.0; Kglc = 0.039 ± 0.003 mL/mL/min,
p = 0.77; day 21: K1 = 0.098±0.003 mL/mL/min, p = 0.092; Kglc =
0.028±0.001 mL/mL/min, p = 0.088). The simultaneous increase of K1
and Kglc indicate that the increase of Kglc is a consequence not only of in-
creased hexokinase activity but also of increased unidirectional transport
of glucose into tissue. Six weeks after stroke, inﬂammation resolved
(BPND = 0.21±0.05, p = 0.18) and metabolism returned to the same
level as two days after the onset of ischemia but before the onset of in-
ﬂammation (K1 = 0.091 ± 0.006 mL/mL/min, p = 0.013; Kglc =
0.026 ± 0.003 mL/mL/min, p = 0.026). Immunohistochemistry showed
that brain tissue was infarcted in this region (Fig. 4).
The region of primary inﬂammation was always part of the region
that appeared as infarcted in the T2weightedMR images (Fig. 2). How-
ever, this region could not be identiﬁed based on the MR images.
Development of CMRglc
We also analyzed the development of CMRglc in the region of primary
inﬂammation (Figs. 3D–F). The time course of the CMRglc is not complete-
ly following the PK11195-BPND time course. In a detailed analysis (not
shown here) we found that CMRglc relative to the blood glucose level
was deregulated after MCAo in two rats (rat 1 and 2 in Table 1) causing
an average increase of CMRglc in the healthy contralateral hemisphere.
However, the time course of CMRglc in the region of primary inﬂamma-
tion relative to CMRglc in contralateral hemisphere (CMRglc,VOI/CMRglc,c)
follows the development of inﬂammation. Statistics for CMRglc,VOI/
CMRglc,c: overall effect (F(5,20) = 20.78, p b 0.001), base line (1.02 ±
0.01), day 2 (0.62 ± 0.05, p b 0.001), day 7 (0.95 ± 0.04, p = 0.14),
day 14 (0.79 ± 0.03, p b 0.001), day 21 (0.74 ± 0.03, p b 0.001), day 42
(0.63 ± 0.05, p b 0.001).
After stroke, glucose consumption correlated signiﬁcantly with the
average binding potential of [11C]PK11195 in the region of primary in-
ﬂammation (Fig. 3F; Pearson correlation of Kglc vs. [11C]PK11195-BPND
at day 2,7,14,21,42 after MCAo: r = 0.65, p = 0.0005, Pearson correla-
tion of CMRglc,VOI/CMRglc,c vs. [11C]PK11195-BPND at days 2, 7, 14, 21,and 42 after MCAo: r = 0.81, p b 0.0001) indicating that the transient
increase in glucosemetabolism reﬂects glucose consumption by inﬂam-
matory cells.
Cellular population of the primary inﬂammation region at day 7
In order to verify that the rise of glucose consumption in the in-
ﬂamed region at day 7 did not reﬂect a transient recovery of neurons
or astrocytes, we reanalyzed data of rats that had been treated in the
same way as rats in the present study, but had been sacriﬁced at day 7
after MCAo (Schroeter et al., 2009). Immunohistochemistry conﬁrmed
that the inﬂamed region identiﬁed by [11C]PK11195 was void of neu-
rons, astrocytes, and oligodendrocytes (negative staining for NeuN,
GFAP, Olig2), exclusively populated by immune cells (all cells Ox-42
and Iba1 positive), which were co-located with the staining for LDH-5,
the enzyme that drives lactate production from pyruvate (Bittar et al.,
1996) (Fig. 5). The upregulation of LDH-5 indicates that these cells me-
tabolize glucose non-oxidatively via glycolysis.
[11C]PK11195-postive and [11C]PK11195-negative inﬂammation region
Only a fraction of the region inﬁltrated by macrophages was labeled
by [11C]PK11195 (Fig. 5). Staining for phagocytic cells, there was no obvi-
ous difference between [11C]PK11195-positive and [11C]PK11195-nega-
tive cells, neither in cell density nor in morphological structure. Regional
comparison of CBF (measured 60 min after MCAo) and [11C]PK11195-
BPND at day 7 shows that in regions where CBF is below ~30% of the nor-
mal CBF, [11C]PK11195-BPND is linearly correlated to CBF (Fig. 6D), indi-
cating that tracer delivery to tissue is limited in these regions and
[11C]PK11195-BPND underestimates the true number of macrophages in
low perfusion regions. The major part of [11C]PK11195 binding is located
in regions with a residual blood ﬂow of 30%–80%.
The observed rise of Kglc during inﬂammation was conﬁned to the
[11C]PK11195-positive fraction of the inﬂamed region (Fig. 2). Note
that the absence of [18F]FDG accumulation implied absent glucose me-
tabolism: tissue not reached by the PET tracer was neither reached by
glucose as the energy substrate. Thus, inﬂammatory cells were only
able to satisfy their energy needs by consumption of glucose where glu-
cose was available.
Discussion
Although it is not surprising that inﬂammatory cells consume glu-
cose to satisfy their energy needs (Wise et al., 1983), it is remarkable
that in regions with insufﬁcient blood ﬂow for neurons and astrocytes
to survive, inﬂammatory cells managed to extract and consume the
same amounts of glucose per time and volume tissue as neurons and as-
trocytes consumed under healthy conditions.
Our results indicate that (1) Inﬂammatory cells seem to rely upon a
very efﬁcient glucose transport system that is capable of extracting high
amounts of glucose even in ischemic tissue. (2) Neurons and astrocytes
in the region of primary inﬂammation died of oxygen and not of glucose
deﬁciency. (3) High glucose consumption in presumably oxygen deﬁ-
cient tissue indicates that glucose taken-up by inﬂammatory cells is
non-oxidativelymetabolized. (4) [11C]PK11195 labels activatedmicrog-
lia and macrophages in tissue with sufﬁcient residual blood ﬂow to de-
liver the tracer, but underestimates inﬂammation in regions with
CBFb~30% of normal.
[11C]PK11195 binds to the translocator protein (TSPO), which is pri-
marily located on the outer mitochondrial membrane of activated mi-
croglia and macrophages. Changes in TSPO expression are related to
alterations in the functional state of mitochondria (Banati et al., 2004).
Unlike microglia and unlike adaptive immune cells (e.g. T cells), macro-
phages can switch to non-oxidative metabolism in hypoxic conditions
(Fumagalli et al., 2015; Riboldi et al., 2013; Sica et al., 2011). In accor-
dance with the results from immunostaining (Fig. 5), it is therefore
62 H. Backes et al. / NeuroImage 128 (2016) 54–62most likely that macrophages are responsible for the transient increase
in glucose consumption that we observe in the ischemic area. However,
the origin of these macrophages (from CNS or hematogenous) is less
clear. Itwas shown in rat brain slices thatwithin 2 hmicroglia can trans-
form into amoeboid macrophages (Stence et al., 2001). Although hyp-
oxia induces autophagic cell death in microglia cultures (Yang et al.,
2014), in vivo hypoxia could trigger the transformation of microglia
intomacrophages. Microglia also have the capacity to become polarized
intoM1-like andM2-like phenotypes (Prinz and Priller, 2014). Thus, the
functional status of these cell populations is not determined by their
origin.
[15O]H2O measurements were only performed immediately before
and up to 1 h after the permanent occlusion of the MCA. The analysis
of the early development of regional CBF after occlusion showed that
major changes in CBF occurred within the ﬁrst 30 min while there
were only minor changes from 30 to 60 min (Walberer et al., 2012).
After permanent MCA occlusion in cats it was shown that CBF changes
between 1 and 24 h were minimal (Heiss et al., 1994). In our study,
we identiﬁed the location of the occluding macrosphere post mortem
and conﬁrmed that the MCA was still blocked at six weeks after occlu-
sion and reperfusion due to ﬂushing away of the occluding obstacle
could be excluded. We therefore assume here that the individual CBF
map of each animal at 60min after permanent occlusionmore or less re-
ﬂects the future situation.
Our ﬁndings could inﬂuence the detection of neuroinﬂammation
and hypo-metabolism in other pathologies. Neurodegenerative diseases
such as Alzheimer’s disease or Parkinson’s disease affect cerebral glu-
cose metabolism and induce inﬂammation. Our observations indicate
that (1) energy metabolism of inﬂammatory cells can mask metabolic
deﬁcits in regions with neuronal damage, and (2) the in vivo detection
of inﬂammation using tracer methods is impaired in severely hypo-
perfused tissue. A recent study on glucose metabolism and inﬂamma-
tion in patients suffering from Parkinson’s disease showed – although
not explicitly discussed by the authors – a mismatch of regions with re-
duced glucosemetabolismand regionswith inﬂammation (Edison et al.,
2013). The comparison of Figs. 1 and 3 in their publication indicates that
on the one hand, regions with the highest level of inﬂammation did not
show a reduction in glucose metabolismwhile on the other hand, those
regions with the most prominent reductions of glucose consumption
did not show [11C]PK11195 binding (Fig. 7). Our own data demonstrate
that intact glucose metabolism in a [11C]PK11195 positive region can be
caused by glucose consumption of inﬂammatory cells, while a lack of
[11C]PK11195 binding regions with impaired glucose consumption
does not necessarily exclude inﬂammation. In summary, previous data
and our current ﬁndings suggest that [18F]FDG and [11C]PK11195 PET
provide complementary information regarding glucose consumption
and neuroinﬂammation. Glucose consumption of inﬂammatory cells
needs to be taken into accountwhen diagnosingneurodegenerative dis-
eases by measuring local metabolism.
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